Sonia Ancoli-Israel1, James K. Walsh, Richard M. Mangano, Masamoto Fujimori. 1. Department of Psychiatry, University of California, San Diego and Veterans Affairs, San Diego Healthcare System, San Diego; the Sleep Medicine and Research Center, St. Luke's Hospital and Department of Psychiatry, St. Louis University, St. Louis, Mo.; and Wyeth-Ayerst Research, Radnor, Pa.
Abstract
BACKGROUND: Insomnia is a very common symptom, particularly in the elderly. Thus, all hypnotic medications should be carefully evaluated in the elderly population. Zaleplon, a new nonbenzodiazepine hypnotic with a short elimination half-life (approximately 1 hour), was evaluated in the current study. METHOD: This multicenter, randomized, placebo-controlled outpatient study evaluated the efficacy and safety of zaleplon, 5 and 10 mg, in elderly patients with insomnia (as defined by DSM-IV); zolpidem, 5 mg, was the active comparator. Sleep was assessed in 549 elderly patients (>/= 65 years old) by using morning questionnaires completed after each of 7 baseline nights during which placebo was given, 14 nights of double-blind treatment, and 7 nights of placebo after discontinuation of active treatment. RESULTS:Zaleplon, 10 mg, and zolpidem, 5 mg, significantly reduced sleep latency during both weeks of the study. Zaleplon, 5 mg, reduced sleep latency only during week 2. Sleep duration was increased with zolpidem, 5 mg, during weeks 1 and 2 and with zaleplon, 10 mg, during week 1. No clinically significant rebound insomnia was observed after discontinuation of treatment with zaleplon, whereas evidence of rebound effects was seen with zolpidem. There was no significant difference between either zaleplon dose and placebo in the frequency of any central nervous system adverse events. CONCLUSION:Zaleplon is effective in reducing latency to sleep without evidence of undesired effects in elderly patients with insomnia.
RCT Entities:
BACKGROUND:Insomnia is a very common symptom, particularly in the elderly. Thus, all hypnotic medications should be carefully evaluated in the elderly population. Zaleplon, a new nonbenzodiazepine hypnotic with a short elimination half-life (approximately 1 hour), was evaluated in the current study. METHOD: This multicenter, randomized, placebo-controlled outpatient study evaluated the efficacy and safety of zaleplon, 5 and 10 mg, in elderly patients with insomnia (as defined by DSM-IV); zolpidem, 5 mg, was the active comparator. Sleep was assessed in 549 elderly patients (>/= 65 years old) by using morning questionnaires completed after each of 7 baseline nights during which placebo was given, 14 nights of double-blind treatment, and 7 nights of placebo after discontinuation of active treatment. RESULTS:Zaleplon, 10 mg, and zolpidem, 5 mg, significantly reduced sleep latency during both weeks of the study. Zaleplon, 5 mg, reduced sleep latency only during week 2. Sleep duration was increased with zolpidem, 5 mg, during weeks 1 and 2 and with zaleplon, 10 mg, during week 1. No clinically significant rebound insomnia was observed after discontinuation of treatment with zaleplon, whereas evidence of rebound effects was seen with zolpidem. There was no significant difference between either zaleplon dose and placebo in the frequency of any central nervous system adverse events. CONCLUSION:Zaleplon is effective in reducing latency to sleep without evidence of undesired effects in elderly patients with insomnia.
Authors: P Rayón; M Serrano-Castro; H del Barrio; C Alvarez; D Montero; M Madurga; R Palop; F J DeAbajo Journal: Ann Pharmacother Date: 1996-10 Impact factor: 3.154
Authors: B Beer; J R Ieni; W H Wu; D Clody; P Amorusi; J Rose; T Mant; J Gaudreault; A Cato; W Stern Journal: J Clin Pharmacol Date: 1994-04 Impact factor: 3.126
Authors: Sonia Ancoli-Israel; Andrew D Krystal; W Vaughn McCall; Kendyl Schaefer; Amy Wilson; Raymond Claus; Robert Rubens; Thomas Roth Journal: Sleep Date: 2010-02 Impact factor: 5.849